

DR. SOLIMAN ABDEL KADER
FAKEEH HOSPITAL COMPANY
(A Saudi Joint Stock Company)

**CONDENSED CONSOLIDATED INTERIM
FINANCIAL STATEMENTS (UNAUDITED)**

For the three-month period ended
31 March 2026

together with the

INDEPENDENT AUDITORS' REVIEW REPORT

DR. SOLIMAN ABDEL KADER FAKEEH HOSPITAL COMPANY
(A Saudi Joint Stock Company)

CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED)
For the three-months period ended 31 March 2026

Index	Page
Independent auditor's report on review of condensed consolidated interim financial statements	1
Condensed consolidated Interim statement of financial position	2
Condensed consolidated Interim statement of profit or loss and other comprehensive income	3
Condensed consolidated Interim statement of changes in equity	4
Condensed consolidated Interim statement of cash flows	5 – 6
Notes to the condensed consolidated interim financial statements	7 – 25



ERNST & YOUNG PROFESSIONAL SERVICES (PROFESSIONAL LLC)
Paid-Up Capital (SR 5,500,000 - Five Million Five Hundred Thousand Saudi Riyal)
King's Road Tower, 13th Floor
King Abdul Aziz Road (Malek Road)
P.O. Box 1994 - Jeddah 21441
Kingdom of Saudi Arabia
Head Office - Riyadh - C.R. No. 1010383821

C.R. No. 4030276644
Tel: +966 12 221 8400
Fax: +966 12 664 4408
ey.ksa@sa.ey.com
<https://www.ey.com>

INDEPENDENT AUDITOR'S REVIEW REPORT ON THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

**To the Shareholders of Dr. Soliman Abdel Kader Fakeeh Hospital Company
(A Saudi Joint Stock Company)**

Introduction

We have reviewed the accompanying interim condensed consolidated statement of financial position of Dr. Soliman Abdel Kader Fakeeh Hospital Company ("the Company") and its subsidiaries (collectively referred to as "the Group") as at 31 March 2026, and the related interim condensed consolidated statements of profit or loss and other comprehensive income, changes in equity and cashflows for the three-month period then ended, and explanatory notes. Management is responsible for the preparation and presentation of these interim condensed consolidated financial statements in accordance with the International Accounting Standard 34, "Interim Financial Reporting" ("IAS 34") as endorsed in the Kingdom of Saudi Arabia. Our responsibility is to express a conclusion on these interim condensed consolidated financial statements based on our review.

Scope of Review

We conducted our review in accordance with the International Standard on Review Engagements 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", as endorsed in the Kingdom of Saudi Arabia. A review of interim financial statement consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing that are endorsed in the Kingdom of Saudi Arabia and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Conclusion

Based on our review, nothing has come to our attention that causes us to believe that the accompanying interim condensed consolidated financial statements are not prepared, in all material respects, in accordance with IAS 34 as endorsed in the Kingdom of Saudi Arabia.

for Ernst & Young Professional Services

Ahmed Ibrahim Reda
Certified Public Accountant
License No. 356



Jeddah: 11 May 2026
24 Thul Qi'dah 1447H


DR. SOLIMAN ABDEL KADER FAKEEH HOSPITAL COMPANY
(A Saudi Joint Stock Company)

CONDENSED CONSOLIDATED INTERIM STATEMENT OF FINANCIAL POSITION


As at 31 March 2026

(All Amounts expressed in thousands of Saudi Riyals, unless otherwise stated)

	<u>Notes</u>	<u>31 March</u> <u>2026</u>	<u>31 December</u> <u>2025</u>
<u>ASSETS</u>			
Property and equipment	5	2,511,781	2,498,755
Right-of-use assets "RoU"	6.1	570,022	492,247
Intangible assets and goodwill	7	548,536	547,568
Investment properties		366	376
Financial asset at amortized cost		300,617	298,126
Prepayments and other non-current assets		24,167	22,244
Other long-term receivables	8	140,315	144,748
		<u>4,095,804</u>	<u>4,004,064</u>
Non-current assets			
Inventories		206,107	196,293
Accounts and other receivables	9	974,663	974,978
Contract assets		68,468	39,798
Prepayments and other current assets		171,411	174,382
Cash and cash equivalents	10	421,911	439,162
		<u>1,842,560</u>	<u>1,824,613</u>
Current assets			
		<u>5,938,364</u>	<u>5,828,677</u>
Total assets			
<u>EQUITY AND LIABILITIES</u>			
<u>EQUITY</u>			
Share capital	11	232,000	232,000
Treasury shares	11.1	(2,000)	(2,000)
Share premium		1,653,473	1,653,473
Retained earnings		1,328,143	1,288,560
		<u>3,211,616</u>	<u>3,172,033</u>
Equity attributable to shareholders of the Company			
Non-controlling interests ("NCI")		414,606	409,353
		<u>3,626,222</u>	<u>3,581,386</u>
Total equity			
<u>LIABILITIES</u>			
Long-term loans	12	334,000	334,000
Lease liabilities	6.2	542,364	481,162
Employees' end of service benefits		321,819	312,996
		<u>1,198,183</u>	<u>1,128,158</u>
Non-current liabilities			
Short-term loans	12	329,427	297,543
Current portion of lease liabilities	6.2	72,210	63,662
Accounts payables		356,193	362,234
Accrued and other current liabilities		317,998	365,403
Provision for Zakat	13	38,131	30,291
		<u>1,113,959</u>	<u>1,119,133</u>
Current liabilities			
		<u>2,312,142</u>	<u>2,247,291</u>
Total liabilities			
		<u>5,938,364</u>	<u>5,828,677</u>
Total equity and liabilities			


Mr. Ammar Faqih
Chairman Board of Directors


Dr. Mazen Fakeeh
President


Mr. Taha Bin Shaukat
Group Chief Financial Officer

The accompanying notes 1 to 24 form an integral part of these condensed consolidated interim financial statements.


DR. SOLIMAN ABDEL KADER FAKEEH HOSPITAL COMPANY
(A Saudi Joint Stock Company)


CONDENSED CONSOLIDATED INTERIM STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME


For the three-month periods ended 31 March 2026

(All Amounts expressed in thousands of Saudi Riyals, unless otherwise stated)

	Notes	For the three-month period ended 31 March	
		2026 (Unaudited)	2025 (Unaudited)
Revenue	14	724,147	701,018
Costs of revenue		(584,251)	(524,882)
Gross profit		139,896	176,136
Other income		3,646	1,641
Selling and marketing expenses		(19,454)	(16,846)
General and administrative expenses	15	(73,951)	(76,781)
Impairment loss on accounts receivables	9.1	(5,529)	(7,169)
Operating profit		44,608	76,981
Finance costs	16.1	(17,176)	(9,926)
Finance income	16.2	6,575	7,720
Profit before zakat		34,007	74,775
Zakat	13	(7,840)	(7,421)
Profit for the period		26,167	67,354
Other comprehensive income:			
<i>Items that will not be reclassified to profit or loss:</i>			
Re-measurement loss on defined benefit obligations		--	--
Total comprehensive income for the period		26,167	67,354
Profit / (loss) for the period attributable to:			
- Shareholders of the Parent Company		38,414	72,204
- Non-controlling interests		(12,247)	(4,850)
		26,167	67,354
Total comprehensive income / (loss) for the period attributable to:			
- Shareholders of the Parent Company		38,414	72,204
- Non-controlling interests		(12,247)	(4,850)
		26,167	67,354
Earnings per share			
Basic and diluted earnings per share	17	0.17	0.31


Mr. Ammar Faqih
Chairman Board of Directors


Dr. Mazen Fakeeh
President


Mr. Taha Bin Shaukat
Group Chief Financial Officer

The accompanying notes 1 to 24 form an integral part of these condensed consolidated interim financial statements.

DR. SOLIMAN ABDEL KADER FAKEEH HOSPITAL COMPANY


(A Saudi Joint Stock Company)


CONDENSED CONSOLIDATED INTERIM STATEMENT OF CHANGES IN EQUITY


For the three-month period ended 31 March 2026

(All Amounts expressed in thousands of Saudi Riyals, unless otherwise stated)

	Attributed to shareholders of the parent				Total	Non-controlling interests	Total equity
	Share capital	Treasury shares	Share premium	Retained earnings			
Balance at 1 January 2025 (Audited)	232,000	(2,000)	1,653,473	1,061,873	2,945,346	374,078	3,319,424
<u>Total comprehensive income for the period</u>							
Profit for the period	--	--	--	72,204	72,204	(4,850)	67,354
Employee share-based payments reserve charged to profit and loss	--	--	--	2,303	2,303	--	2,303
<u>Transactions with shareholders</u>							
Additional capital contribution by NCI	--	--	--	--	--	23,379	23,379
Balance at 31 March 2025 (Unaudited)	<u>232,000</u>	<u>(2,000)</u>	<u>1,653,473</u>	<u>1,136,380</u>	<u>3,019,853</u>	<u>392,607</u>	<u>3,412,460</u>
Balance at 1 January 2026 (Audited)	232,000	(2,000)	1,653,473	1,288,560	3,172,033	409,353	3,581,386
<u>Total comprehensive income for the period</u>							
Profit for the period	--	--	--	38,414	38,414	(12,247)	26,167
Employee share-based payments reserve charged to profit and loss	--	--	--	1,169	1,169	--	1,169
<u>Transactions with shareholders</u>							
Additional capital contribution by NCI	--	--	--	--	--	17,500	17,500
Balance at 31 March 2026 (Unaudited)	<u>232,000</u>	<u>(2,000)</u>	<u>1,653,473</u>	<u>1,328,143</u>	<u>3,211,616</u>	<u>414,606</u>	<u>3,626,222</u>


 Mr. Ammar Faqih
 Chairman Board of Directors


 Dr. Mazen Fakeeh
 President


 Mr. Taha Bin Shaukat
 Group Chief Financial Officer

The accompanying notes 1 to 24 form an integral part of these interim condensed consolidated financial statements.

DR. SOLIMAN ABDEL KADER FAKEEH HOSPITAL COMPANY
(A Saudi Joint Stock Company)

CONDENSED CONSOLIDATED INTERIM STATEMENT OF CASH FLOWS

For three-months period ended 31 March 2026

(All Amounts expressed in thousands of Saudi Riyals, unless otherwise stated)

Notes	For the three-month period ended 31 March 2026 (Unaudited)	For the three-month period ended 31 March 2025 (Unaudited)
Cash flows from operating activities		
	34,007	74,775
<i>Adjustments for:</i>		
- Depreciation on property and equipment	5.1 31,803	24,467
- Depreciation on right-of-use assets	6.1 16,990	15,500
- Amortization of Intangible assets	1,973	1,827
- Depreciation on investment properties	10	10
- Provision for employee's end of service benefits	15,441	12,688
- Impairment loss on accounts receivables	9.1 5,529	7,169
- Loss on disposal of property and equipment and RoU	(29)	214
- Non-Cash Share based Payment plan expense	15, 11.1 1,169	2,303
- Discounting impact of DAAM scholarship program	400	322
- Net finance costs	10,601	2,206
	117,894	141,481
<i>Changes in operating assets and liabilities:</i>		
- Inventories	(9,814)	(12,749)
- Accounts and other receivables	(5,214)	35,933
- Contract assets	(28,670)	(68,429)
- Other long-term receivables	4,033	(205)
- Prepayments and other current assets	2,971	16,498
- Accounts payables	(6,041)	(29,272)
- Accrued and other current liabilities	(45,963)	15,552
Cash generated from operating activities	29,196	98,809
Interest paid	(9,469)	(2,884)
Interest paid on lease	6.2 (9,149)	(7,936)
Employees' end of service benefits paid	(6,618)	(2,912)
Zakat paid	13.b --	(28)
Net cash generated from operating activities	3,960	85,049
Cash flows from investing activities:		
Additions to property and equipment	5.1 (46,763)	(190,733)
Additions to intangible assets	(1,136)	(986)
Prepayments and other non-current assets	(1,923)	206
Interest received	16.2 4,084	8,777
Proceeds from disposal of property and equipment	151	59
Net cash used in investing activities	(45,587)	(182,677)
Cash flows from financing activities:		
Additional capital contribution by NCI	17,500	23,379
Repayment of principal portion of lease liability	6.2 (25,008)	(26,799)
Proceeds from long-term loans	--	8,500
Repayment of long-term loans	--	(1,000)
Net movement in short term loans	31,884	(39,789)
Net cash generated from / (used in) financing activities	24,376	(35,709)
Net (decrease) in cash and cash equivalents	(17,251)	(133,337)
Cash and cash equivalents at beginning of the period	439,162	533,785
Cash and cash equivalents at the end of the period	10 421,911	400,448

DR. SOLIMAN ABDEL KADER FAKEEH HOSPITAL COMPANY
(A Saudi Joint Stock Company)

CONDENSED CONSOLIDATED INTERIM STATEMENT OF CASHFLOWS (continued)

For three-months period ended 31 March 2026

(All Amounts expressed in thousands of Saudi Riyals, unless otherwise stated)

	<u>Notes</u>	For the three-month period ended 31 March 2026 (Unaudited)	For the three-month period ended 31 March 2025 (Unaudited)
Major non-cash transactions:			
Addition to right-of-use assets and lease liabilities	6.2	<u>94,858</u>	<u>6,823</u>
Borrowing cost capitalized	5.4	<u>3,871</u>	<u>8,067</u>



Mr. Ammar Faqih
Chairman Board of Directors



Dr. Mazen Fakeeh
President



Mr. Taha Bin Shaukat
Group Chief Financial Officer

The accompanying notes 1 to 24 form an integral part of these condensed consolidated interim financial statements.

DR. SOLIMAN ABDELKADER FAKEEH HOSPITAL COMPANY

(A Saudi Joint Stock Company)

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED)

At 31 March 2026

(All Amounts expressed in thousands of Saudi Riyals, unless otherwise stated)

1. GENERAL

Dr. Soliman Abdel Kader Fakeeh Hospital Company (the “Parent Company”) is a Saudi Joint Stock Company formed under the laws of the Kingdom of Saudi Arabia and is registered in the Commercial Registry in Jeddah under No. 4030014511 and Unified Identification Number 7001713341 on 11 Rabi II 1398H (20 March 1978). The Parent Company was converted from a Sole Proprietorship to a Saudi closed Joint Stock Company under the Ministerial Decision No. 28 dated 1 Safar 1433H (corresponding to 26 December 2011) approving the announcement of the establishment of Dr. Soliman Abdel Kader Fakeeh Hospital Company (A Saudi “closed Joint Stock Company”). On 27 Duhl Qadah 1445H (corresponding to 4 June 2024), the Parent Company successfully converted from a “Saudi Closed Joint Stock Company” to a “Saudi Joint Stock Company.” Following this, on 28 Duhl Qadah 1445H (corresponding to 5 June 2024), the Parent Company completed its Initial Public Offering (IPO), and its shares were listed on the Tadawul Primary Market, commencing trading under the symbol 4017 and ISIN code SA562GSHUOH7.

These condensed consolidated interim financial statements include assets, liabilities and the results of the operations of the Parent Company and its following subsidiaries collectively referred to as “the Group”. The condensed interim financial statements of the subsidiaries are prepared for the same reporting period and accounting policies as that of the Parent Company.

The Group’s registered office and principal place of business is Jeddah.

The principal activity of the Group is managing, establishing and operating hospitals, clinics, medical, educational and training centers. In addition to the above, the Group is also managing and operating medical services, analysis and radiology laboratory and managing and establishing pharmacies, wholesale and retail of medical equipment, maintenance of IT equipment and software related services.

The Group has three reportable segments including medical services, education and trading & retail business (note 20).

As at 31 March 2026 and 31 December 2025, the Group has investments in the following subsidiaries:

<u>Name of subsidiaries</u>	<u>Country of Incorporation</u>	<u>Effective holding</u>		<u>Principal activities</u>
		<u>2026</u>	<u>2025</u>	
Al-Farabi Special Health Care Company Limited (“Farabi”)	Saudi Arabia	70%	70%	Healthcare service provider
Dr. Soliman Abdel Kader Fakeeh Information Technology Company (Formerly, Kameda Arabia Company Limited)	Saudi Arabia	100%	100%	IT equipment and software services
Dr. Soliman Abdel Kader Fakeeh Family Medicine Centers (“FMH”)	Saudi Arabia	90%	90%	Healthcare service provider
Dr. Soliman Abdel Kader Fakeeh Medical Education Company Limited (“FMEC”)	Saudi Arabia	80%	80%	Medical education service provider
Dr. Mazen Fakeeh Complementary Health Care Company Limited (“FCHC”)	Saudi Arabia	100%	100%	Wholesale and retail of medical equipment
Al Toor Medical Services Company (“Al Toor”)	Saudi Arabia	51%	51%	Healthcare service provider
Saudi Airlines Company for Medical Services (“SMS”)	Saudi Arabia	75%	75%	Healthcare service provider
Al-Faraj Pharmaceutical Medical Company (“Al-Faraj”)	Saudi Arabia	89.82%	89.82%	Trading in pharmaceutical products

DR. SOLIMAN ABDELKADER FAKEEH HOSPITAL COMPANY

(A Saudi Joint Stock Company)

**NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
(UNAUDITED)**

At 31 March 2026

(All Amounts expressed in thousands of Saudi Riyals, unless otherwise stated)

1. GENERAL (continued)

<u>Name of subsidiaries</u>	<u>Country of Incorporation</u>	<u>Effective holding</u>		<u>Principal activities</u>
		<u>2026</u>	<u>2025</u>	
Advanced Horizon Contracting Company ("AHC")	Saudi Arabia	100%	100%	Construction and contracting
Golden Union Medical Company ("GUMC")	Saudi Arabia	100%	100%	Emergency medical services
Dr. Soliman Fakeeh Hospital Medical Company ("DSFH Riyadh")	Saudi Arabia	68.36%	68.36%	Healthcare service provider
White Lines Medical Company ("WLMC")	Saudi Arabia	74.25%	74.25%	Trading in pharmaceutical products
Fakeeh Vision Company Limited ("FVCL")	Saudi Arabia	100%	100%	Trading of spectacles and cosmetics
Dr. Soliman Abdel Kader Fakeeh Home Health Care Company ("FHHC")	Saudi Arabia	100%	100%	Home health care
Advance Lines Medical - ALM	Saudi Arabia	74.25%	74.25%	Trading in pharmaceutical products
Modern Algorithms Solutions for Information Technology Company	Saudi Arabia	100%	100%	Healthcare IT software services provider
Masar Dr. Sulaiman Fakeeh Hospital ("MDSFH")	Saudi Arabia	100%	100%	Healthcare service provider
Integrated care solution "ICS"(a)	Saudi Arabia	100%	100%	Healthcare IT software services provider
Cyber Immunity Services Company ("CISC") (a)	Saudi Arabia	70%	70%	IT equipment and software services
CareCom Company ("CC") (a)	Saudi Arabia	100%	100%	Healthcare service provider

(a) During the year 2025, the Group established three new subsidiaries registered in the Kingdom of Saudi Arabia. The operations have not yet commenced as of period end.

2. BASIS OF PREPARATION**2.1 Basis of preparation**

These condensed consolidated interim financial statements have been prepared in accordance with International Accounting Standards 34 as issued by International Accounting Standards Board ("IFRS Accounting Standards"), (IAS) 34 "Interim Financial Reporting" that is endorsed in Kingdom of Saudi Arabia and other standards and pronouncements that are issued by the Saudi Organization for Chartered and Professional Accountants ("SOCPA") and should be read in conjunction with the Group's annual consolidated financial statements as at and for the year ended 31 December 2025 ("last annual Financial Statements").

These condensed consolidated interim financial statements do not include all of the information required for a complete set of annual consolidated financial statements prepared in accordance with International Financial Reporting Standards ('IFRS') as endorsed in the Kingdom of Saudi Arabia. However, selected accounting policies and explanatory notes are included to explain events and transactions that are significant to an understanding of the changes in the Group's financial position and performance since the last annual consolidated financial statements. In addition, consolidated results for the interim period ended 31 March 2026, are not necessarily indicative of the results that may be expected for the financial year ending 31 December 2026.

DR. SOLIMAN ABDELKADER FAKEEH HOSPITAL COMPANY

(A Saudi Joint Stock Company)

**NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
(UNAUDITED)**

At 31 March 2026

(All Amounts expressed in thousands of Saudi Riyals, unless otherwise stated)

2. BASIS OF PREPARATION (continued)

2.2 Basis of measurement

These condensed consolidated interim financial statements have been prepared under the historical cost basis. Further, the condensed consolidated interim financial statements are prepared using the accrual basis of accounting and the going concern assumption.

2.3 Significant judgments, estimates and assumptions

The preparation of these condensed consolidated interim financial statements requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets and liabilities, income and expenses, accompanying disclosures, including disclosure of contingent liabilities. However, uncertainty about these assumptions and estimates could result in outcomes that could require a material adjustment to the carrying amount of the asset or liability in the future periods. Actual results may differ from these estimates.

Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to estimates are recognised prospectively.

The significant judgements made by management in applying the Group's accounting policies and the key sources of estimation of uncertainty were the same as those described in the last annual consolidated financial statements for the year ended 31 December 2025.

2.4 Functional and presentation currency

The Group's condensed consolidated interim financial statements are presented in Saudi Arabian Riyals, which is also the Parent Company's functional currency. For each entity, the Group determines the functional currency, and items included in the financial statements of each entity are measured using that functional currency.

3. NEW STANDARDS, INTERPRETATIONS AND AMENDMENTS ADOPTED BY THE GROUP

Following amendments to IFRS Accounting Standards were effective on or after 1 January 2026, but they did not have a material effect on the interim condensed consolidated financial statements:

Classification and Measurement of Financial Instruments – Amendments to IFRS 9 and IFRS 7

In May 2024, the IASB issued Amendments to IFRS 9 and IFRS 7, Amendments to the Classification and Measurement of Financial Instruments (the Amendments). The Amendments include:

- Clarifications of the requirements for recognition and derecognition of financial assets and financial liabilities. In particular, a financial liability is derecognised on the 'settlement date' and an accounting policy choice is introduced (if specific conditions are met) to derecognise financial liabilities settled using an electronic payment system before the settlement date
- Additional guidance on how the contractual cash flows for financial assets with environmental, social and corporate governance (ESG) and similar features should be assessed
- Clarifications on what constitute 'non-recourse features' and what are the characteristics of contractually linked instruments
- The introduction of disclosures for financial instruments with contingent features and additional disclosure requirements for equity instruments classified at fair value through other comprehensive income (OCI)

The amendments had no impact on the Group's interim condensed consolidated financial statements.

DR. SOLIMAN ABDELKADER FAKEEH HOSPITAL COMPANY

(A Saudi Joint Stock Company)

**NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
(UNAUDITED)**

At 31 March 2026

(All Amounts expressed in thousands of Saudi Riyals, unless otherwise stated)

3. NEW STANDARDS, INTERPRETATIONS AND AMENDMENTS ADOPTED BY THE GROUP (Continued)

Annual Improvements to IFRS accounting Standards – Volume 11

In July 2024, the IASB issued nine narrow scope amendments as part of its periodic maintenance of IFRS accounting standards. The amendments include clarifications, simplifications, corrections or changes to improve consistency in IFRS 1 First-time Adoption of International Financial Reporting Standards, IFRS 7 Financial instruments: Disclosure and its accompanying Guidance on implementing IFRS 7, IFRS 9 Financial Instruments, IFRS 10 Consolidated Financial Statements and IAS 7 Statements of Cash Flows.

The amendments had no impact on the Group's interim condensed consolidated financial statements.

Contracts Referencing Nature -dependent Electricity – Amendments to IFRS 9 and IFRS 7

In December 2024, the IASB issued Amendments to IFRS 9 and IFRS 7 – Contracts Referencing Nature dependent Electricity. The amendments apply only to contracts that reference nature-dependent electricity, and they:

- Clarify the application of the 'own-use' requirements for in-scope contracts
- Amend the designation requirements for a hedged item in a cash flow hedging relationship for in -scope contracts
- Add new disclosure requirements to enable investors to understand the effect of these contracts on a company's financial performance and cash flows

— The amendments had no impact on Group's interim condensed consolidated financial statements.

4. MATERIAL ACCOUNTING POLICIES

The accounting policies applied in these interim condensed consolidated financial statements are the same as those applied in the Group's annual consolidated financial statements as at and for the year ended 31 December 2025, except for the adoption of new standards effective as of 1 January 2026 (as detailed in note 3). The Group has not early adopted any standard, interpretation or amendment that has been issued but is not yet effective.

DR. SOLIMAN ABDELKADER FAKEEH HOSPITAL COMPANY

(A Saudi Joint Stock Company)

**NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
(UNAUDITED)**

At 31 March 2026

(All Amounts expressed in thousands of Saudi Riyals, unless otherwise stated)

5. PROPERTY AND EQUIPMENT

5.1 Reconciliation of carrying amounts:

	31 March 2026 (Unaudited)	31 December 2025 (Audited)
Carrying amount at beginning of the period / year	2,498,755	2,095,843
Additions during the period / year	46,763	520,329
Disposals during the period / year	(129)	(3,357)
Transfer to Intangibles during the period / year	(1,805)	(2,503)
Depreciation charge for the period / year	(31,803)	(111,557)
Carrying amount at the end of the period / year	2,511,781	2,498,755

5.2 Category-wise carrying amounts are as follows:

	31 March 2026 (Unaudited)	31 December 2025 (Audited)
Land	387,521	387,521
Buildings and leasehold improvements	1,000,555	998,615
Medical and support equipment	485,299	479,068
Furniture and fixtures	43,637	35,323
Motor vehicles	16,663	17,651
Office equipment	26,189	24,034
Computers	49,704	50,528
Capital work-in-progress (note 5.3)	502,213	506,015
	2,511,781	2,498,755

5.3 Capital work-in-progress mainly represents the construction work being carried out for the Group's expansion projects and upgrading the existing infrastructure and facilities.

5.4 During the period ended 31 March 2026, an amount of SR 3.9 million (31 December 2025: SR 29.1 million) was capitalized as borrowing cost.

6. RIGHT-OF-USE ASSETS AND LEASE LIABILITIES

6.1 Right-of-use assets

a) Reconciliation of carrying amounts

	31 March 2026 (Unaudited)	31 December 2025 (Audited)
Cost:		
Balance at the beginning of the period / year	738,866	708,076
Additions during the period / year	94,858	67,490
Modifications during the period / year	--	(22,639)
Terminations for the period / year	(20,901)	(14,061)
Balance at the end of the period / year	812,823	738,866

DR. SOLIMAN ABDELKADER FAKEEH HOSPITAL COMPANY

(A Saudi Joint Stock Company)

**NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
(UNAUDITED)**

At 31 March 2026

(All Amounts expressed in thousands of Saudi Riyals, unless otherwise stated)

6. RIGHT-OF-USE ASSETS AND LEASE LIABILITIES (continued)

6.1 Right-of-use assets (continued)

a) Reconciliation of carrying amounts (continued)

	31 March 2026 (Unaudited)	31 December 2025 (Audited)
<u>Accumulated depreciation:</u>		
Balance at the beginning of the period / year	246,619	202,738
Depreciation charge for the period / year	16,990	62,690
Modifications	--	(10,651)
Terminations for the period / year	(20,808)	(8,158)
Balance at the end of the period / year	242,801	246,619
Carrying amounts at the end of the period / year	570,022	492,247

6.2 Lease liabilities

	31 March 2026 (Unaudited)	31 December 2025 (Audited)
Balance at the beginning of the period / year	544,824	541,394
Additions during the period / year	94,858	67,490
Interest expenses for the period / year (Note 16.1)	6,830	23,109
Interest capitalized for the period / year	2,319	9,041
Modifications	--	(14,460)
Terminations for the period / year	(100)	(6,178)
Interest paid during the period / year	(9,149)	(32,150)
Payments during the period / year	(25,008)	(43,422)
Balance at the end of the period / year	614,574	544,824

Lease liabilities are presented in the condensed consolidated interim statement of financial positions as follows:

	31 March 2026 (Unaudited)	31 December 2025 (Audited)
Non-current portion of lease liabilities	542,364	481,162
Current portion of lease liabilities	72,210	63,662
	614,574	544,824

7 INTANGIBLE ASSETS AND GOODWILL

	31 March 2026 (Unaudited)	31 December 2025 (Audited)
Goodwill	488,816	488,816
Medical licenses	17,575	18,243
Customer relationships	16,924	17,247
Computer software	14,421	12,462
Software under development	10,800	10,800
	548,536	547,568

DR. SOLIMAN ABDELKADER FAKEEH HOSPITAL COMPANY

(A Saudi Joint Stock Company)

**NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
(UNAUDITED)**

At 31 March 2026

(All Amounts expressed in thousands of Saudi Riyals, unless otherwise stated)

7 INTANGIBLE ASSETS AND GOODWILL (CONTINUED)

The Group performs its annual impairment test in December or when circumstances indicate that the carrying value may be impaired which ever earlier. The Group's impairment test for goodwill is based on value-in-use calculations. The key assumptions used to determine the recoverable amount for the different cash generating units were disclosed in the annual consolidated financial statements for the year ended 31 December 2025. There were no significant changes on key assumptions and sensitivity information disclosed in the annual consolidated financial statements for the year ended 31 December 2025.

8 OTHER LONG-TERM RECEIVABLES

	31 March 2026 (Unaudited)	31 December 2025 (Audited)
Non-current portion of receivables under DAAM scholarship Program	<u>140,315</u>	<u>144,748</u>

9 ACCOUNTS AND OTHER RECEIVABLES

	31 March 2026 (Unaudited)	31 December 2025 (Audited)
Trade receivables	1,093,237	1,092,796
Trade receivables - related parties (note 18)	24,517	23,351
	<u>1,117,754</u>	<u>1,116,147</u>
Less: allowance for impairment losses	<u>(143,091)</u>	<u>(141,169)</u>
	<u>974,663</u>	<u>974,978</u>

9.1 The movement of allowance for impairment losses is as follows:

	31 March 2026 (Unaudited)	31 December 2025 (Audited)
Balance at beginning of the period / year	141,169	131,079
Provision for impairment losses during the period / year	5,529	24,420
Written off during the period / year	<u>(3,607)</u>	<u>(14,330)</u>
Balance at end of the period / year	<u>143,091</u>	<u>141,169</u>

9.2 The contract asset primarily relates to operating project contract with customers.

10 CASH AND CASH EQUIVALENTS

Cash and cash equivalents include cash and bank balances.

	31 March 2026 (Unaudited)	31 December 2025 (Audited)
Cash in hand	5,901	3,992
Cash at banks - current accounts	120,510	167,170
Short-term deposits	<u>295,500</u>	<u>268,000</u>
	<u>421,911</u>	<u>439,162</u>

DR. SOLIMAN ABDELKADER FAKEEH HOSPITAL COMPANY

(A Saudi Joint Stock Company)

**NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
(UNAUDITED)**

At 31 March 2026

(All Amounts expressed in thousands of Saudi Riyals, unless otherwise stated)

10 CASH AND CASH EQUIVALENTS (CONTINUED)

At each reporting date, all bank balances are assessed to have low credit risk as they are held with reputable and high credit rating domestic banking institutions and there has been no history of default with any of the Group's bank balances. Therefore, the probability of default based on forward-looking factors and any loss given defaults are considered to be negligible.

- 10.1 Short-term deposits are made at the available short-term deposit rates for varying periods of between one day to three months, depending on the immediate cash requirements of the Group.

11 SHARE CAPITAL

As at 31 March 2026, the share capital of the Parent Company comprised of 232 million shares at a nominal value of SR 1 per share (31 December 2025: 232 million shares).

	No. of Shares	Amount
Dr. Mazen Soliman Abdel Kader Fakeeh	71,649	71,649
Mr. Ammar Sulayman A. Faqih	71,649	71,649
Dr. Manal Soliman Abdel Kader Fakeeh	35,824	35,824
Fakeeh Real Estate Company Limited (A Saudi Limited Liability Company)	20	20
Al Solimania United Company Limited (A Saudi Limited Liability Company)	20	20
Employee Share Ownership Plan (note 11.1)	2,000	2,000
Free Float	50,838	50,838
	232,000	232,000

11.1 Employee Share Ownership Program

On 23 November 2023 (corresponding to 9 Jumada Al Awwal 1445H), the Parent Company's Extraordinary General Assembly approved the issuance of 2 million New Shares through the capitalization of SR 2 million of retained earnings and retain them as treasury shares. These treasury shares will be allocated to the Employee Share Program for the Group in accordance with the applicable terms and conditions. The Employee Share Program will be set-up after the required approvals, to attract and retain outstanding employees. The Extraordinary General Assembly authorized the Board of Directors to implement the Employee Share Program, subject to the related laws.

During the first quarter of 2025, the Long-Term Incentive Plan "LTIP" detailed policy was approved by the Board of Directors and was ratified by the EGM in the 1st quarter of 2026. This LTIP cycle will run for 3 years starting from 1st January 2025 and despite the existence of a cliff, the fair value of award will be recognized as Non-Cash Share based Payment during the three years period proportionately and on a quarterly basis.

The LTIP is solely settled through Shares. The number of shares allocated to each employee is communicated at the Grant date to the Employees, however, the actual number of shares at the end of the 3-year period will vary based on the actual vesting conditions as such the LTIP falls within the "Equity-settled share-based payment transactions".

- 11.2 During the year 2025, the general assembly approved the distribution of cash dividends amounting to SAR 69 million representing a dividend of SAR 0.30 for each issued share excluding shares under the employee share ownership program. The distribution was approved by the general assembly meeting held on 25 June 2025.

DR. SOLIMAN ABDELKADER FAKEEH HOSPITAL COMPANY

(A Saudi Joint Stock Company)

**NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
(UNAUDITED)**

At 31 March 2026

(All Amounts expressed in thousands of Saudi Riyals, unless otherwise stated)

12 LOANS AND BORROWINGS

The group is financed through facilities from local banks which include both long-term and short-term loans. These facilities are Sharia compliant and are subject to Saudi Arabia interbank Offered Rate "SIBOR" plus a margin. Certain loans are subject to certain bank covenants which are fully compliant at the reporting date.

Movement summary of the loans and borrowings during the period / year is as follows:

	31 March <u>2026</u> (Unaudited)	31 December <u>2025</u> (Audited)
Balance at beginning of the period / year	631,543	536,500
Proceeds during the period / year	36,384	748,111
Payments made during the period / year	<u>(4,500)</u>	<u>(653,068)</u>
Balance at end of the period / year	<u>663,427</u>	<u>631,543</u>

The term of long-term loans are from 5 to 6 years. The first instalment is payable in Q2 2027.

13 ZAKAT**a) Charge for the period:**

Zakat included in the condensed consolidated interim statement of profit or loss and other comprehensive income are comprised of the following:

	31 March <u>2026</u> (Unaudited)	31 March <u>2025</u> (Unaudited)
Charge for the period	<u>7,840</u>	<u>7,421</u>

b) The movement in the accrual for Zakat is as follows:

	31 March <u>2026</u> (Unaudited)	31 December <u>2025</u> (Audited)
Balance at beginning of the period / year	30,291	25,484
Charge for current period / year	7,840	32,335
Payments during the period / year	--	<u>(27,528)</u>
Balance at end of the period / year	<u>38,131</u>	<u>30,291</u>

DR. SOLIMAN ABDELKADER FAKEEH HOSPITAL COMPANY

(A Saudi Joint Stock Company)

**NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
(UNAUDITED)**

At 31 March 2026

(All Amounts expressed in thousands of Saudi Riyals, unless otherwise stated)

13 ZAKAT (continued)**c) Status of assessments**

All the below companies have filed their Zakat return for the years up to 31 December 2025 and received unrestricted Zakat certificates for to the same periods.

<u>Company name</u>	<u>Financial years open for Zakat assessment</u>
Dr. Soliman Abdel Kader Fakeeh Hospital Company	2020 – 2025
Al-Farabi Special Health Care Company Limited	2020 – 2025
Dr. Soliman Kader Fakeeh Information Technology Company	2020 – 2025
Dr. Soliman Abdel Kader Fakeeh Family Medicine Centers	2020 – 2025
Dr. Soliman Abdel Kader Fakeeh Medical Education Company Limited	2021 – 2025
Dr. Mazen Fakeeh Complementary Health Care Company Limited	2021 – 2025
Al Toor Medical Services Company	2020, 2022 – 2025
Saudi Airlines Company for Medical Services	2020 – 2025
Al-Faraj Pharmaceutical Medical Company	2020 – 2025
Advanced Horizon Contracting Company	2021 – 2025
Golden Union Medical Company	2021 – 2025
Dr. Soliman Fakeeh Hospital Medical Company	2020 – 2025
Dr. Soliman Abdel Kader Fakeeh Home Health Care Company	2023 – 2025
White Lines Medical Company	2023 – 2025
Fakeeh Vision	2023 – 2025

DR. SOLIMAN ABDELKADER FAKEEH HOSPITAL COMPANY

(A Saudi Joint Stock Company)

**NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
(UNAUDITED)**

At 31 March 2026

(All Amounts expressed in thousands of Saudi Riyals, unless otherwise stated)

14 REVENUE***Disaggregation of revenue from contracts with customers***

In the following table, revenue from contracts with customers is disaggregated by major service lines and timing of revenue recognition, all revenue is primarily generated in the Kingdom of Saudi Arabia:

	For the three-month period ended 31 March 2026 (Unaudited)	For the three-month period ended 31 March 2025 (Unaudited)
Revenue from Health care operations	648,814	637,365
Revenue from Medical related services	28,473	32,334
Revenue from Education services	31,124	28,883
Revenue from IT and other services	15,736	2,436
	<u>724,147</u>	<u>701,018</u>
	For the three-month period ended 31 March 2026 (Unaudited)	For the three-month period ended 31 March 2025 (Unaudited)
Timing of revenue recognition		
Point in time	418,369	444,589
Over time	305,778	256,429
Revenue from contracts with customers	<u>724,147</u>	<u>701,018</u>

15 GENERAL AND ADMINISTRATIVE EXPENSES

	For the three-month period ended 31 March 2026 (Unaudited)	For the three-month period ended 31 March 2025 (Unaudited)
General and administrative expenses	72,782	74,478
Non-Cash Share based Payment (Note 11.1)	1,169	2,303
	<u>73,951</u>	<u>76,781</u>

DR. SOLIMAN ABDELKADER FAKEEH HOSPITAL COMPANY

(A Saudi Joint Stock Company)

**NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
(UNAUDITED)**

At 31 March 2026

(All Amounts expressed in thousands of Saudi Riyals, unless otherwise stated)

16 FINANCE COST AND INCOME**a. Finance Costs**

	For the three-month period ended 31 March <u>2026</u> (Unaudited)	For the three-month period ended 31 March <u>2025</u> (Unaudited)
Interest expenses – loan	10,346	4,166
Interest expenses – lease liabilities (Note 6.2)	6,830	5,760
	<u>17,176</u>	<u>9,926</u>

b. Finance Income

Finance income is recognized using effective interest method. Time deposits are placed with financial institutions in the Kingdom of Saudi Arabia; these deposits are sharia compliant.

	For the three-month period ended 31 March <u>2026</u> (Unaudited)	For the three-month period ended 31 March <u>2025</u> (Unaudited)
Income from deposits and government Sukuk	<u>6,575</u>	<u>7,720</u>

17 EARNINGS PER SHARE

Basic earnings per share (EPS) is calculated by dividing profit for the period attributable to ordinary equity holders of the Parent Company by the weighted average number of ordinary shares in issue outstanding during the period.

	For the three-month period ended 31 March <u>2026</u> (Unaudited)	For the three-month period ended 31 March <u>2025</u> (Unaudited)
Profit for the period attributable to ordinary equity holders of the Parent	<u>38,414</u>	<u>72,204</u>
Weighted average number of ordinary shares in issue	<u>230,000</u>	<u>230,000</u>
Basic and diluted earnings per share	<u>0.17</u>	<u>0.31</u>

DR. SOLIMAN ABDELKADER FAKEEH HOSPITAL COMPANY

(A Saudi Joint Stock Company)

**NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
(UNAUDITED)**

At 31 March 2026

(All Amounts expressed in thousands of Saudi Riyals, unless otherwise stated)

18 RELATED PARTY TRANSACTIONS AND BALANCES

The Group, in the normal course of business, enters into transactions with other entities that fall within the definition of a related party contained in International Accounting Standard 24 as endorsed in KSA. Related parties comprise of the shareholders of the Group, being parent Company, its subsidiaries and associates, and other companies with common directorship with significant influence on other companies and key management personnel. Transactions with related parties arise mainly from goods/services received and various business arrangements undertaken at management approved contractual terms.

Transactions with key management personnel***Key management personnel compensation***

a) Key management personnel remuneration and compensation comprised of the following:

	31 March 2026 (Unaudited)	31 March 2025 (Unaudited)
Short-term employee benefits	4,834	4,926
Board of Directors' and related committee remuneration	453	360
Post-employment benefits	312	362
	<u>5,599</u>	<u>5,648</u>

DR. SOLIMAN ABDELKADER FAKEEH HOSPITAL COMPANY

(A Saudi Joint Stock Company)

**NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
(UNAUDITED)**

At 31 March 2026

(All Amounts expressed in thousands of Saudi Riyals, unless otherwise stated)

18. RELATED PARTY TRANSACTIONS AND BALANCES (continued)

b) Related party transactions

<u>Related party</u>	<u>Nature of transactions</u>	<u>Amount of transactions</u>	
		31 March 2026 (Unaudited)	31 March 2025 (Unaudited)
Shareholder	Lease rental payments	22,168	22,168
Non - controlling Shareholder	Revenue	9,299	10,002
Entities under common ownership of the Group's controlling shareholder	Royalty Charges	600	600
Entities under common ownership of the Group's controlling shareholder	SLA Charges	563	300
Entities under common ownership of the Group's controlling shareholder	Purchases	506	1,436
Entities under common ownership of the Group's controlling shareholder	Lease rental payments	99	165
Entities under common ownership of the Group's controlling shareholder	Payments made on behalf of the related party	88	232
Shareholder	Payments made on behalf of the	-	427
Entities under common ownership of the Group's controlling shareholder	Revenue	-	369
Non - controlling Shareholder	Lease rental payments	-	200

DR. SOLIMAN ABDELKADER FAKEEH HOSPITAL COMPANY

(A Saudi Joint Stock Company)

**NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
(UNAUDITED)**

At 31 March 2026

(All Amounts expressed in thousands of Saudi Riyals, unless otherwise stated)

18. RELATED PARTY TRANSACTIONS AND BALANCES (continued)

c) Related party closing balances

<u>Name</u>	<u>Balance as of</u>	
	31 March 2026 (Unaudited)	31 December 2025 (Audited)
<u>Due from related parties – (Trade and other receivables)</u>		
Non - controlling Shareholder	25,918	25,261
Entities under common ownership of the Group's controlling shareholder	15,419	14,063
Shareholder	4,093	3,532
Others	92	80
	45,522	42,936
	31 March 2026 (Unaudited)	31 December 2025 (Audited)
<u>Due to related parties – (Accounts payables, Accrued and other current liabilities)</u>		
Entities under common ownership of the Group's controlling shareholder	734	1,434
Non - controlling Shareholder	223	--
	957	1,434

19 COMMITMENTS AND CONTINGENCIES

As at 31 March 2026 the Group has:

- Outstanding letters of guarantee amounting to SR 39.5 million (31 December 2025: SR 38.7 million).
- Outstanding letters of credit amounting to SR 4.2 million (31 December 2025: SR 4.9 million).
- Commitments for capital work in progress of SR 161.6 million (31 December 2025: SR 163 million) mainly relating to construction, renovation and upgradation of buildings.

As at 31 March 2026, there are no significant litigations and claims against the Group.

DR. SOLIMAN ABDELKADER FAKEEH HOSPITAL COMPANY

(A Saudi Joint Stock Company)

**NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
(UNAUDITED)**

At 31 March 2026

(All Amounts expressed in thousands of Saudi Riyals, unless otherwise stated)

20 BUSINESS SEGMENTS

As the operations of the Group are conducted in the Kingdom of Saudi Arabia, accordingly, for management purposes, the Group is organized into business units based on its products and services and has three reportable segments. Operating segments is determined based on the Group's internal reporting to the Chief Operating Decision Maker ("CODM"). The CODM has been determined to be the President as he is primarily responsible for the allocation of resources to segments and the assessment of the performance of each of the segments. The CODM uses underlying income as reviewed at monthly Executive Committee and Performance meetings as the key measure of the segments' results as it reflects the segments' performance for the period under evaluation. Revenue and segment profit is a consistent measure within the Group. The identified key segments are medical services, education, trading and retail.

Information regarding the results of each reportable segment is included below. Performance is measured based on segment revenues, as included in the internal management reports that are reviewed by the top management. The following table presents segment information (assets, liabilities, revenue and net income) for each of the business segments as at and for the three-month period ended 31 March:

31 March 2026 (Unaudited)	Reportable Segments				Total
	Medical services	Education	Trading, Retail & Others	Un- Allocated	
Revenues	663,668	31,524	122,109	--	817,301
Inter-segment revenue eliminations	(6,411)	(400)	(86,343)	--	(93,154)
Segment revenue	657,257	31,124	35,766	--	724,147
Direct costs	(555,756)	(14,827)	(82,556)	--	(653,139)
Inter-segment direct costs	6,411	--	62,477	--	68,888
Segment cost	(549,345)	(14,827)	(20,079)	--	(584,251)
Segment gross profit	107,912	16,297	15,687	--	139,896
Operating expenses	--	--	--	(93,405)	(93,405)
Impairment loss on accounts receivables	(3,950)	(464)	(1,115)	--	(5,529)
Other income	-	-	--	3,646	3,646
Operating profit	103,962	15,833	14,572	(89,759)	44,608
Finance cost	--	--	--	(17,176)	(17,176)
Finance income	--	--	--	6,575	6,575
Zakat	--	--	--	(7,840)	(7,840)
Profit for the period	103,962	15,833	14,572	(108,200)	26,167
31 March 2026 (Unaudited)					
Total assets	5,511,833	203,955	222,576	--	5,938,364
Total liabilities	2,003,199	93,173	168,892	46,878	2,312,142

DR. SOLIMAN ABDELKADER FAKEEH HOSPITAL COMPANY

(A Saudi Joint Stock Company)

**NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
(UNAUDITED)**

At 31 March 2026

(All Amounts expressed in thousands of Saudi Riyals, unless otherwise stated)

20. BUSINESS SEGMENTS (continued)

31 March 2025 (Unaudited)	<u>Reportable Segments</u>				<u>Total</u>
	<u>Medical services</u>	<u>Education</u>	<u>Trading, Retail & Others</u>	<u>Un-Allocated</u>	
Revenues	650,769	29,206	91,382	--	771,357
Inter-segment revenue eliminations	(4,096)	(322)	(65,921)	--	(70,339)
Segment revenue	646,673	28,884	25,461	--	701,018
Direct costs	(498,338)	(14,352)	(64,765)	--	(577,455)
Inter-segment direct costs	4,096	--	48,477	--	52,573
Segment cost	(494,242)	(14,352)	(16,288)	--	(524,882)
Segment gross profit	152,431	14,532	9,173	--	176,136
Operating expenses	--	--	--	(93,627)	(93,627)
Impairment loss on accounts receivables	(5,374)	(420)	(1,375)	--	(7,169)
Other income	--	--	--	1,641	1,641
Operating profit	147,057	14,112	7,798	(91,986)	76,981
Finance Income	--	--	--	(9,926)	(9,926)
Finance cost	--	--	--	7,720	7,720
Zakat	--	--	--	(7,421)	(7,421)
Profit for the period	147,057	14,112	7,798	(101,613)	67,354
31 December 2025 (Audited)					
Total assets	5,429,658	199,293	199,726	--	5,828,677
Total liabilities	1,706,935	108,749	394,997	36,610	2,247,291

The Group's top management reviews internal management reports of each strategic business unit at least quarterly. Segment results that are reported to the top management include items directly attributable to a segment as well as those that can be allocated on a reasonable basis.

21 FAIR VALUE OF FINANCIAL ASSETS AND FINANCIAL LIABILITIES

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value measurement is based on the presumption that the transaction takes place either:

- In the accessible principal market for the asset or liability, or
- In the absence of a principal market, in the most advantageous accessible market for the asset or liability
- Fair value information of the Group's financial instruments is analysed below:

DR. SOLIMAN ABDELKADER FAKEEH HOSPITAL COMPANY

(A Saudi Joint Stock Company)

**NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
(UNAUDITED)**

At 31 March 2026

(All Amounts expressed in thousands of Saudi Riyals, unless otherwise stated)

21. FAIR VALUE OF FINANCIAL ASSETS AND FINANCIAL LIABILITIES (continued)

The Group uses the following hierarchy for determining and disclosing the fair value of financial instruments:

Level 1: quoted prices in active markets for the same or identical instrument that an entity can access at the measurement date;

Level 2: quoted prices in inactive markets for similar assets and liabilities or valuation techniques for which all significant inputs are based on observable market data; and

Level 3: valuation techniques for which any significant input is not based on observable market data.

There were no transfers between level 1 and level 3 during the three-month period 31 March 2026 (31 December 2025: nil). There were no financial assets or financial liabilities classified under level 2 (31 December 2025: nil).

There were no changes in valuation techniques during the period. As at 31 March 2026, the financial assets of the Group are comprised of financial assets at amortized cost, prepayments and other current assets, accounts and other receivables, contract assets and cash and cash equivalents which are recorded at amortised cost and their carrying values approximates their fair values. The Group's financial liabilities include long-term and short-term loans, accounts payable, accruals and other liabilities.

22. SUBSEQUENT EVENTS

Subsequent to period, the Group announced the signing of a binding Share Purchase Agreement to acquire 100% of Dr. Mohammed Bin Rashid Al Fagih & Partners Company for a total cash consideration of SAR 1.60 billion. The acquisition is subject to meeting certain conditions precedent including required legal and regulatory approvals.

Furthermore, subsequent to period end, the Board of Directors approved to distribute cash dividends amounting to SAR 75.9 million, representing SAR 0.33 per share excluding treasury shares, subject to the approval of the shareholders at the General Assembly.

23. GEOPOLITICAL DEVELOPMENTS

During the current period, geopolitical tensions in parts of the Middle East have increased. Public communications from government and regulatory authorities have continued to emphasize the resilience of the economy and the continuation of business operations across key sectors, supported by established business continuity and risk management frameworks.

Fakeeh Care Group has been monitoring the potential implications of these geopolitical developments on its operations, financial position and financial performance. Based on the information available as at the date of these consolidated financial statements, management has not identified any material impact on the Group's operations for the current period, although the extent of any effect on future periods remains uncertain. Accordingly, it is not currently practicable to reliably estimate the full financial effect, if any, of these developments on future periods.

Management has also considered the impact of these matters on the Group's ability to continue as a going concern and has concluded that the going concern basis of preparation remains appropriate.

DR. SOLIMAN ABDELKADER FAKEEH HOSPITAL COMPANY

(A Saudi Joint Stock Company)

**NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
(UNAUDITED)**

At 31 March 2026

(All Amounts expressed in thousands of Saudi Riyals, unless otherwise stated)

24. DATE OF AUTHORIZATION FOR ISSUE

The interim condensed consolidated financial statements were approved and authorized for issue by the Board of Directors of Parent Company on 5 May 2026, corresponding to 18 Thul-Qi'dah 1447H.



Mr. Ammar Faqih
Chairman Board of Directors



Dr. Mazen Fakeeh
President



Mr. Taha Bin Shaukat
Group Chief Financial Officer